Table 1

Demographics and clinical characteristics of PIBD cohorts

Baseline characteristicsPIBD cohort A (n=42)PIBD cohort B (n=26)
Age, median (IQR)14.5 (14–16)15.0 (14–16)
Sex, n (%)
 Female18 (42.8)11 (42.3)
IBD subtype, n (%)
 CD33 (78.6)16 (61.5)
 UC9 (21.4)10 (38.4)
Disease activity, n (%) *
 Remission
 Mild4 (9.5)3 (11.5)
Treatment, n (%)
 Infliximab monotherapy18 (42.8)11 (42.3)
 Infliximab with methotrexate/azathioprine†24 (57.1)14 (53.8)
 Adalimumab monotherapy
 Adalimumab with methotrexate†1 (3.8)
 Doses of BNT162b2 SARS-CoV-2 vaccine received12
 Interval between 2 doses, median in days (range)56 (22–105)
  • *Disease activity was assessed using PUCAI/PCDAI SCORES; REMISSION <10 and mild 10–30.

  • †Methotrexate (mean±SD, 14.4 mg±4.8), azathioprine (mean±SD, 83.8 mg±38.4).

  • CD, crohn's disease ; PCDAI, Pediatric Crohn's Disease Activity Index; PIBD, paediatric IBD; PUCAI, Pediatric Ulcerative Colitis Activity Index; UC, ulcerative colitis.